Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024

BRAINSTORM CELL THERAPEUTICS INC.

Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.
Base salary $450k/year; option for 60k shares and 30k restricted stock grant.
Eligible for annual cash bonus up to 35% of base salary and $10k signing bonus.
Previously founded BioCentriq, a CDMO acquired for $73M by GC Holdings.
Appointment supports operational readiness for NurOwn® Phase 3b ALS study.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hartoun Hartounian

Executive Vice President and Chief Operating Officer

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2024-06-24
Filed: June 20, 2024, 7:59 PM ET

On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hartoun Hartounian was appointed as Executive Vice President and Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..

Action: appointed
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).

View on SEC.gov

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-073484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.